A Yiotakis

Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.

P Cuniasse, L Devel, A Makaritis, 2005, Biochimie.

RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.

P Corvol, A Yiotakis, V Dive, 2001, The Journal of pharmacology and experimental therapeutics.

RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

P Corvol, P Cuniasse, A Yiotakis, 1999, Proceedings of the National Academy of Sciences of the United States of America.